TABLE 1.
Overview of JAK inhibitors tested in clinical trials and under preclinical evaluation for spondyloarthropathies and related diseases.
| JAK inhibitor | Target | Trial/disease | Status | PMID/NCT trial number | Trial status |
| Tofacitinib | JAK1/JAK3 | Rheumatoid Arthritis | Approved | (28–31) | |
| Psoriatic Arthritis | Approved | (32, 33) | |||
| Axial Spondyloarthritis | Phase III | NCT03502616 | Active | ||
| Ulcerative Colitis | Phase III | (34) | |||
| Crohn’s disease | Phase II | (35) | |||
| Psoriasis | Phase III | (36) | |||
| Uveitis | Phase II | NCT03580343 | Active | ||
| Baricitinib | JAK1/JAK2 | Rheumatoid Arthritis | Approved | (37, 38) | |
| Filgotinib | JAK1 | Rheumatoid Arthritis | Phase III | (39) | |
| Axial Spondyloarthritis | Phase III | NCT04483687, NCT04483700 | Not started, Not started | ||
| Psoriatic Arthritis | Phase III | NCT04115748, NCT04115839 | Active, Recruiting | ||
| Ulcerative Colitis | Phase III | NCT02914522 | Completed | ||
| Crohn’s disease | Phase III | NCT02914561 | Recruiting | ||
| Uveitis | Phase II | NCT03207815 | Recruiting | ||
| Upadacitinib | JAK1 | Rheumatoid Arthritis | Approved | (40–42) | |
| Axial Spondyloarthritis | Phase III | NCT04169373 | Recruiting | ||
| Psoriatic Arthritis | Phase III | NCT03104374, NCT03104400 | Active, Active | ||
| Ulcerative Colitis | Phase III | NCT03653026, NCT02819635 | Recruiting, Recruiting | ||
| Crohn’s disease | Phase III | NCT03345836, NCT03345849 | Recruiting, Recruiting | ||
| Pefacitinib | Pan-JAK | Rheumatoid Arthritis | Phase III | (43, 44) | |
| Psoriasis | Phase II | (45) | |||
| Ulcerative Colitis | Phase II | (46) | |||
| Deucravacitinib (BMS-986165) | TYK2 | Psoriatic Arthritis | Phase II | NCT03881059 | Active |
| Psoriasis | Phase II | (47) | |||
| Abrocitinib (PF-04965842) | JAK1 | Psoriasis | Phase II | (48), NCT02201524 | Terminated |
| Itacitinib (INCB039110) | JAK1 | Rheumatoid Arthritis | Phase II | NCT01626573 | Completed |
| Psoriasis | Phase II | NCT01634087 | Completed | ||
| PF-06651600 | JAK3 | Rheumatoid Arthritis | Phase II | NCT04413617 | Not started |
| Ulcerative Colitis | Phase II | NCT02958865 | Recruiting | ||
| Crohn’s disease | Phase II | NCT03395184 | Recruiting | ||
| SHR0302 | JAK1 | Rheumatoid Arthritis | Phase III | NCT04333771 | Not started |
| Axial Spondyloarthritis | Phase II/III | NCT04481139 | Not started | ||
| Ulcerative Colitis | Phase II | NCT03675477 | Recruiting | ||
| Crohn’s disease | Phase II | NCT03677648 | Recruiting | ||
| PF-06826647 | TYK2 | Psoriasis | Phase II | NCT03895372 | Recruiting |
| Ulcerative Colitis | Phase II | NCT04209556 | Recruiting | ||
| Brepocitinib (PF-06700841) | JAK1/TYK2 | Psoriatic Arthritis | Phase II | NCT03963401 | Active |
| Psoriasis | Phase II | NCT02969018 | Completed | ||
| Ulcerative Colitis | Phase II | NCT02958865 | Recruiting | ||
| Crohn’s disease | Phase II | NCT03395184 | Recruiting | ||
| NDI-031407 | TYK2 | SKG mouse model | Preclinical | (14) | |
| NDI-031232 | TYK2 | Preclinical | |||
| SAR-20347 | JAK1/TYK2 | Psoriasis mouse model | Preclinical | (49) |